Able View Global, a Cayman-domiciled brand-management partner for international beauty labels selling into China, faces its first 180-day Nasdaq minimum-bid-price cure window closing June 2, 2026 (the compliance deadline announced in the December 9, 2025 deficiency notice), and the response approved at the March 13, 2026 extraordinary general meeting is a reverse share split of up to 1-for-200, with the exact ratio left to board discretion. The Class B shares closed at $0.685 on August 15, 2026, well below the $1.00 threshold and down 61% from the 52-week high of $1.77, which means the board retains the option to push the ratio to the maximum end of the range rather than a token 1-for-5.
The load-bearing question for the equity is not the compliance clock itself but the operating cash-flow signature underneath it: FY2025 revenue of $105.2 million was 17% below the FY2024 print of $126.8 million, gross margin held at 11.3%, operating cash flow from continuing operations was a $3.6 million use, and net income from continuing operations was a $2.8 million loss (the $0.8 million positive net result came only from a $4.8 million gain on the June 27, 2025 disposal of subsidiary Shanghai Jingyue pulling the consolidated bottom line into the black). The thesis frame is straightforward: the market is paying $33.8 million of equity value (49.4 million shares at $0.685) for a brand-management franchise that ran a continuing-operations loss in three of the past four years and just saw its largest brand partner concentrate to a single name (Clarins, 10%+ of FY2025 revenue), and the next data point that tests this is the ratio the board selects and the 10-consecutive-trading-day $1.00 print that follows.
We see the equity as a probability-weighted option on three distinct events: a successful bid-price cure that preserves the Nasdaq listing, an H1 2026 top-line stabilization off the H1 2025 base of $46.7 million (which was 24% below the $61.3 million H1 2024 print), and a board-led cost reset the new management team (including a CFO change reflected in recent 6-K filings) can execute. The bear case is straightforward: a 1-for-200 reverse split at $0.685 takes the share count from 49.4 million to roughly 247,000 shares (making continued listing under any meaningful float standard a separate problem) and the underlying business does not stabilize, in which case the cure is technical and the equity re-rates lower on a post-split float-shock. The next data point that tests this is the board's ratio selection, expected before the June 2, 2026 deadline, and the H1 2026 interim filing window in the September-October 2026 timeframe.